Diant Pharma
OperatingDiant Pharma Inc.
Biotech · Manchester, CT
DIANT® Pharma is a Biopharma solutions company advancing nanotherapy manufacturing. Our technology integrates multiple unit operations into a scalable, continuous, and automated process for the encapsulation of advanced medicines. This enables precise delivery, enhanced stability, and controlled release across diverse applications, including nucleic acid-based vaccines and therapies, small-molecule anti-cancer drugs, controlled-release peptides, and antibodies for autoimmune diseases. Alongside our innovative technology, DIANT® provides contract development services to help biotech partners optimize and scale production for a wide range of therapeutic applications.
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Cap table
Share counts as of May 8, 2026| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Series Seed Preferred Stockpreferred | 1,658,332 | 1 | 100.0% | $1.54Mar 2023 |
Principal holders% as the filing states it, May 8, 2026
- Antonio Costa2,600,000 Common Stock31.5%of company
- Everyone else (not named in filings)68.5%
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
6 people
• President, Chief Investment Officer BK Capital, LLC • VP, Priv. Clients Invest., TD
• CEO, Kineticos Ventures • President of Sharp Clinical Services • VP and GM at Catalent
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 2 annual reports (FY2024–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.